Price movement over the last 24 hours
Alcon AG vs Johnson Controls International PLC — how do they compare? Alcon AG trades at $66.87 (market cap $32.69B), while Johnson Controls International PLC trades at $139.57 (market cap $85.79B). The key difference: Johnson Controls International PLC is far larger — about 2.6× Alcon AG's market cap, and Johnson Controls International PLC pays the higher dividend (1.14%). Which is the better fit depends on your goals.
| ALC | JCI | |
|---|---|---|
Market Cap | $32.69B | $85.79B |
Sector | Health | Industrials |
52-Week High | $92.22 | $148.21 |
52-Week Low | $62.02 | $103.24 |
Enterprise Value | $36.28B | $94.62B |
Dividend Yield | 0.54% | 1.14% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Johnson Controls International (JCI) trades at $140.62, down 0.1% on the day, with strong analyst support showing 62% buy ratings and a consensus price target of $153.67. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $1.19 surpassing the $1.12 estimate. The company maintains solid profitability with a 14.45% net income margin and recently announced a $0.40 dividend payable in July 2026. Technical indicators show a bullish trend with support at $139 and resistance at $145.
JCI presents a favorable investment case with earnings momentum, strong analyst conviction, and exposure to growing markets like data center cooling. Key risks include elevated valuation multiples (P/E of 43.65) and increasing debt-to-asset ratios. The stock's current price offers approximately 9% upside to consensus targets, though investors should monitor execution on revenue growth projections and competitive pressures in the building solutions sector.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →